CAJ | 학술논문

目的：评价利妥昔单抗（R）联合FND方案与CHOP方案治疗MALT淋巴瘤的疗效与安全性。方法：将入组初治MALT淋巴瘤患者随机分入CHOP方案组及FND方案组，并根据是否加用利妥昔单抗分为4组：FND组、R-FND组、CHOP组、R-CHOP组。治疗后定期随访，评估无失败生存（FFS）、总生存（OS）。结果：54例患者中，FND组与CHOP组比较，治疗总有效率分别为57.1%、46.2%（P=0.25），R-FND组与R-CHOP组比较，治疗总有效率分别为92.3%、85.7%（P=0.19）。中位随访32.4个月，FND组与CHOP组3年FFS率分别为35.9%和34.7%（P=0.39）；R-FND组与R-CHOP组3年FFS率分别为69.8%和75.5%（P=0.01）。结论：FND与CHOP方案疗效相当。两方案联合利妥昔单抗，有效率差异不明显，但R-CHOP方案在无失败生存更具优势，且耐受性优于R-FND方案。
목적：평개리타석단항（R）연합FND방안여CHOP방안치료MALT림파류적료효여안전성。방법：장입조초치MALT림파류환자수궤분입CHOP방안조급FND방안조，병근거시부가용리타석단항분위4조：FND조、R-FND조、CHOP조、R-CHOP조。치료후정기수방，평고무실패생존（FFS）、총생존（OS）。결과：54례환자중，FND조여CHOP조비교，치료총유효솔분별위57.1%、46.2%（P=0.25），R-FND조여R-CHOP조비교，치료총유효솔분별위92.3%、85.7%（P=0.19）。중위수방32.4개월，FND조여CHOP조3년FFS솔분별위35.9%화34.7%（P=0.39）；R-FND조여R-CHOP조3년FFS솔분별위69.8%화75.5%（P=0.01）。결론：FND여CHOP방안료효상당。량방안연합리타석단항，유효솔차이불명현，단R-CHOP방안재무실패생존경구우세，차내수성우우R-FND방안。
Objective:To study the efficacy of rituximab(R)plus FND chemotherapy and rituximab plus CHOP chemotherapy for MALT lymphoma.Method:The group initially treated MALT lymphoma patients were randomly divided into the CHOP group and the FND group.According to whether the addition of rituximab were divided into 4 groups:FND group, R-FND group,CHOP group,R-CHOP group.Regular follow-up after treatment,failure free survival(FFS),overall survival(OS)were evaluated.Result:There were 54 patients enrolled onto the study.Overall response rates were 57.1%, 46.2%for FND group and CHOP group(P=0.25),92.3%and 85.7%for R-FND group and R-CHOP group(P=0.19). After a median follow-up of 32.4 months,3-year FFS were 35.9%,34.7%for FND group and CHOP group(P=0.39). And 69.8%,75.5% for R-FND group and R-CHOP group(P=0.01).Conclusion:FND regimen has same efficacy to CHOP regimen in overall response rates and FFS.But R-CHOP regimen is superior to R-FND regimen in terms of 3-year FFS. In addition,R-CHOP regimen has a better risk-benefit ratio compared with R-FND regimen.